KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Change in Cash (2018 - 2025)

Historic Change in Cash for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $11.8 million.

  • Adaptive Biotechnologies' Change in Cash rose 15446.68% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year increase of 13294.51%. This contributed to the annual value of -$17.2 million for FY2024, which is 2968.65% up from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Change in Cash is $11.8 million, which was up 15446.68% from -$7.5 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Change in Cash registered a high of $141.1 million during Q3 2022, and its lowest value of -$127.6 million during Q4 2022.
  • For the 5-year period, Adaptive Biotechnologies' Change in Cash averaged around -$3.6 million, with its median value being $2.5 million (2025).
  • Within the past 5 years, the most significant YoY rise in Adaptive Biotechnologies' Change in Cash was 32841.63% (2022), while the steepest drop was 86546.45% (2022).
  • Over the past 5 years, Adaptive Biotechnologies' Change in Cash (Quarter) stood at $16.7 million in 2021, then plummeted by 865.46% to -$127.6 million in 2022, then skyrocketed by 81.47% to -$23.6 million in 2023, then skyrocketed by 141.27% to $9.8 million in 2024, then increased by 21.37% to $11.8 million in 2025.
  • Its Change in Cash stands at $11.8 million for Q3 2025, versus -$7.5 million for Q2 2025 and $2.5 million for Q1 2025.